ArticleCost effectiveness and resource allocation : C/E2016

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema.

Georgia Kourlaba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.